Table 3.

Evolution of biomarkers on CART-133 treatment

Plasma Biomarker	Baseline	D 7	D 14
VEGF	319.06(78.8–847.79)	868(110.51–2164.68)	892.05(140.81–2599.69)
p	N/A	0.001	0.007
sVEGFR2	5715.625(2334.54–8483.41)	6106.279(2886.39–8272.27)	5252.74(3025.47–6988.43)
p	N/A	0.112	0.02
SDF-1	1625.745(1300.32–2019.64)	1768.425(1517.65–2658.47)	1655.455(1301.68–2217.48)
p	N/A	﹤0.0001	0.267
bFGF	21.01(13.74–157.95)	22.42(9.47–140.14)	37.05(13.57–138.69)
p	N/A	0.133	0.459
PDGF BB	260.51(120.6–348.53)	241.17(111.78–333.47)	253.26(118.62–317.62)
p	N/A	0.043	0.122
EPC	109.77(47.62–179.69)	45.055(27.65–119.57)	13.11(1.97–92.37)
p	N/A	0.001	﹤0.0001
IFN-γ	6.01(3.87–8.07)	6.42(5.05–22.57)	6.83(5.24–27.87)
p	N/A	0.01	0.01

VEGF, vascular endothelial growth factor; sVEGFR, soluble form of VEGF receptors; SDF-1, stromal cell–derived factor-1; bFGF, fibroblast growth factor; PDFG, platelet-derived growth factor; EPCs, endothelial progenitor cells; IFN, interferon. P values are from exact one-sample Wilcoxon test. Data are shown as median concentrations and interquartile ranges in pg/mL in plasma for biomarkers. Significant changes in biomarkers are shown in bold. N = 18.